Neuronostics develops BioEP, a patented digital biomarker platform for epilepsy diagnosis and prognosis. BioEP analyses background EEG activity using eight predefined computational biomarkers derived from peer-reviewed neuroscience, providing objective clinical decision support when routine EEG is inconclusive. The platform is UKCA-marked (UK), MOHAP-cleared (UAE), ISO 13485 certified and is pursuing FDA clearance via the De Novo pathway. Neuronostics was named Most Transformative HealthTech Company at the OBN Awards 2025 and won the Epilepsy Foundation of the USA Shark Tank Competition in 2024.
Neuronostics: Venture Capital Funding History
Neuronostics
Neuronostics
- Health
- Bristol, United Kingdom
- £3m
- neuronostics.com
- Update Information
More venture news
- 16 Nov 2026

ZyaZya lands a £12m Series A round led by Astanor to turn sugar in food into prebiotic fibre
Series AHealth - 4 Nov 2026

SurghiveSurghive raises a £320k seed round led by SFC Capital to train surgeons on any robotic surgery system
SeedHealth - 3 Nov 2026

1nhaler1nhaler lands a £2m follow-on round led by Archangels to test its pop-up cardboard asthma inhaler in patients
Follow-onHealth
